Table 2.
Clinical, laboratory and treatment characteristics of the PsA and RA patients included in the study.
| Characteristic | PsA n = 215 |
RA n = 215 |
|---|---|---|
| Type of arthritis at diagnosis | ||
| Oligoarthritisa, n (%) | 76 (35.4) | |
| RA-like, n (%) | 122 (56.7) | N/A |
| Axialb only, n (%) | 14 (6.5) | |
| DIP only, n (%) | 3 (1.4) | |
| Tender joints count, mean ± SDc | 1.8 ± 2.9 | 1.8 ± 3.4 |
| Swollen joints count, mean ± SDc | 1.1 ± 2.3 | 1.4 ± 2.9 |
| Other features | ||
| Body surface areac, mild/moderate/severed; n (%) | 174 (80.9)/39 (18.1)/2 (0.9) | |
| Axial involvementb, n (%) | 73 (33.9) | |
| DIP involvement, n (%) | 13 (6.0) | |
| Dactylitis, n (%) | 42 (19.5) | NA |
| Enthesitis, n (%) | 47 (21.9) | |
| Nail involvement, n (%) | 68 (31.6) | |
| Eye manifestations, n (%) | 6 (2.8) | |
| Bowel manifestations, n (%) | 11 (5.1) | |
| Laboratory features | ||
| ESR, mm/h; mean (SD)c | 22.0 (18.9) | 22.8 (21.4) |
| CRP, mg/l; mean (SD)c | 4.1 (3.9) | 11.4 (4.9) |
| Positive RF, n (%) | N/A | 111/207 (53.6) |
| Anti-CCPs, n (%) | N/A | 80/155 (51.6) |
| Treatment e |
PsA
n = 215 |
RA
n = 215 |
| Methotrexate, n (%) | 112 (52.1) | 138 (64.2) |
| Sulfasalazine, n (%) | 6 (2.8) | 2 (0.9) |
| Cyclosporine, n (%) | 13 (6.0) | 1 (0.4) |
| Leflunomide, n (%) | 19 (8.8) | 23 (10.7) |
| Hydroxychloroquine, n (%) | 1 (0.5) | 41 (19.1) |
| Anti-TNF, n (%) | 39 (18.1) | 55 (25.6) |
| Anti-CD20, n (%) | 0 (0.0) | 6 (2.8) |
| Anti-IL6R, n (%) | 0 (0.0) | 23 (10.7) |
| Abatacept, n (%) | 2 (0.9) | 12 (5.6) |
| Anti-IL-17, n (%) | 15 (7.0) | 0 (0.0) |
| Anti-IL-23/-12, n (%) | 10 (4.7) | 0 (0.0) |
| Apremilast, n (%) | 13 (6.1) | 0 (0.0) |
| Current use of glucocorticoidsf, n (%) | 53 (24.7) | 152 (70.7) |
| Past use of glucocorticoids, n (%) | 61 (28.4) | 53 (24.7) |
| Past use of cDMARDs, number; median (IQR) | 1 (1–1) | 1 (1–2) |
| Past use of bDMARDs, number; median (IQR) | 1 (1–2) | 2 (1–3) |
Arthritis in ⩽4 joints.
Defined as presence of radiological findings (sacroiliitis or spondylitis/syndesmophytes) in X-rays or magnetic resonance imaging.
At the time of inclusion to the study.
Mild: <3% body surface area (BSA); moderate: 3–10% BSA; severe: >10% BSA.
Treatment received at the time of inclusion to the study.
Mean ± SD dose was 3.6 ± 1.3 mg/day prednisolone or equivalent.
bDMARD, biologic disease modifying anti-rheumatic drug; CCP, cyclic citrullinated peptide; cDMARD, conventional disease modifying anti-rheumatic drug; CRP, C-reactive protein; DIP, distal interphalangeal; ESR, erythrocyte sedimentation rate; IL, interleukin; IL6R, interleukin 6 receptor; IQR, interquartile range; mm/h, millimetres per hour; n, number; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor.